Related Experiment Videos
Expression biomarkers for clinical efficacy and outcome prediction in cancer
Kathryn J Strand1, Hanif Khalak, Jeffrey W Strovel
1Avalon Pharmaceuticals, Inc., 20358 Seneca Meadows Parkway, Germantown, MD 20878, USA.
Abstract:
Progress in cancer treatment has been slow, and the outlook for curing cancer is only marginally different from the situation a decade ago. Paradoxically, although the pharmaceutical industry has stepped up costly discovery research and drug development, approvals are on the decline and pipelines are dwindling. In an effort to reduce the number of drug failures and curtail burgeoning R&D costs, drug companies are exploring the use of biomarkers to evaluate toxicity and efficacy earlier in the development process. Biomarkers hold promise for optimization in dosing, adverse event prediction, efficacy evaluation, lead prioritization, and mechanism-of-action profiling of drug candidates. Furthermore, clinicians can use biomarkers to monitor patient response in clinical trials. In this perspective article, the authors explore the applications of cancer-related expression biomarkers in drug discovery and discuss how this will impact the industry and benefit the patient.
Insights
Cancer drug development faces challenges, but biomarkers offer a promising solution. These markers can improve drug efficacy, safety, and patient outcomes in cancer research.
Area of Science:
- Oncology
- Biomarker Discovery
- Pharmaceutical Research
Background:
- Cancer treatment progress remains slow, with limited improvement in cure rates over the past decade.
- Despite increased investment in pharmaceutical research and development (R&D), drug approvals are declining, and development pipelines are shrinking.
- High R&D costs and frequent drug failures necessitate innovative approaches in drug discovery.
Purpose of the Study:
- To explore the application of cancer-related expression biomarkers in drug discovery.
- To discuss the impact of biomarkers on the pharmaceutical industry.
- To highlight the potential benefits of biomarkers for cancer patients.
Main Methods:
- This perspective article reviews the current landscape of biomarker utilization in cancer drug development.
- It analyzes how biomarkers can be integrated into earlier stages of the R&D process.
- The authors discuss the role of expression biomarkers in evaluating drug candidates.
Main Results:
- Biomarkers show significant promise for optimizing drug dosing and predicting adverse events.
- They can enhance efficacy evaluation, lead prioritization, and mechanism-of-action profiling of potential cancer drugs.
- Biomarkers enable clinicians to effectively monitor patient responses during clinical trials.
Conclusions:
- The strategic use of cancer-related expression biomarkers can mitigate drug failures and reduce R&D costs.
- Biomarkers are crucial for improving the efficiency and success rate of cancer drug discovery.
- Ultimately, biomarkers are expected to accelerate the delivery of more effective cancer therapies to patients.
